{"name":"SpringWorks Therapeutics, Inc.","slug":"springworks","ticker":"SWTX","exchange":"NASDAQ","domain":"springworkstx.com","description":"SpringWorks Therapeutics, Inc. (SWTX) is a clinical-stage biopharmaceutical company focused on developing innovative therapies for rare diseases and oncology. The company's pipeline includes several promising candidates, including nirogacestat and mirdametinib. SpringWorks Therapeutics has established itself as a key player in the rare disease and oncology markets, with a strong presence in the US and a growing global reach.","hq":"Stamford, CT","founded":0,"employees":"","ceo":"Saqib Islam","sector":"Rare Disease / Oncology","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$3.1B","metrics":{"revenue":290000000,"revenueGrowth":3417.3,"grossMargin":0,"rdSpend":200518000,"netIncome":-258131000,"cash":69751000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2024"},"revenueBreakdown":[],"timeline":[{"date":"2024-01-01","label":"Ogsiveo first approved","drug":"Ogsiveo","drugSlug":"nirogacestat","type":"approval","sentiment":"positive"},{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"nirogacestat patent cliff ($0.0B at risk)","drug":"nirogacestat","type":"patent_expiry","sentiment":"negative"},{"date":"2032-06-01","label":"mirdametinib patent cliff ($0.0B at risk)","drug":"mirdametinib","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"Nirogacestat oral tablet","genericName":"Nirogacestat oral tablet","slug":"nirogacestat-oral-tablet","indication":"Desmoid tumors (aggressive fibromatosis)","status":"phase_3"},{"name":"Ogsiveo","genericName":"NIROGACESTAT","slug":"nirogacestat","indication":"progressing desmoid tumors","status":"marketed"}]}],"pipeline":[{"name":"Nirogacestat oral tablet","genericName":"Nirogacestat oral tablet","slug":"nirogacestat-oral-tablet","phase":"phase_3","mechanism":"Nirogacestat inhibits gamma-secretase, reducing the production of Notch intracellular domain and downstream signaling that drives abnormal cell proliferation in desmoid tumors.","indications":["Desmoid tumors (aggressive fibromatosis)"],"catalyst":""},{"name":"Ogsiveo","genericName":"NIROGACESTAT","slug":"nirogacestat","phase":"marketed","mechanism":"Nirogacestat works by blocking the gamma secretase enzyme, which is involved in the development and progression of desmoid tumors.","indications":["progressing desmoid tumors"],"catalyst":""}],"recentEvents":[{"date":"2023-02-23","type":"regulatory","headline":"FDA Grants Fast Track Designation to Nirogacestat for Desmoplastic Spinal Cord Astrocytoma","summary":"The FDA granted fast track designation to nirogacestat for the treatment of desmoplastic spinal cord astrocytoma, a rare and aggressive form of brain cancer.","drugName":"nirogacestat","sentiment":"positive"},{"date":"2022-12-15","type":"earnings","headline":"SpringWorks Therapeutics Reports Third Quarter 2022 Financial Results","summary":"SpringWorks Therapeutics reported its third quarter 2022 financial results, with a net loss of $24.4 million and a cash balance of $434.8 million.","drugName":"","sentiment":"neutral"},{"date":"2022-09-01","type":"deal","headline":"SpringWorks Therapeutics Enters into Collaboration and Option Agreement with Pfizer","summary":"SpringWorks Therapeutics entered into a collaboration and option agreement with Pfizer to develop and commercialize nirogacestat for the treatment of desmoplastic spinal cord astrocytoma.","drugName":"nirogacestat","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxPYU1iejI4b0xhMzVkVm5pbjZ6RW9aYU9JdnhnbXVNd2htbUN2Tmx4VEhqbkdXSmF4dkxfSERKaXNWZ3FnWU84Ni1Xc29qd29GMXZWWjVMT05US1paSUJwYzhfajFaOG1CRUhoRmpjb2JmdEdPYVZJa1FnSHQ2YnJCSHE5SFE5d1NUbmtYUg?oc=5","date":"2025-07-01","type":"pipeline","source":"Merck Group","summary":"Merck Completes Acquisition of SpringWorks Therapeutics to Accelerate Sustainable Growth of its Healthcare Business - Merck Group","headline":"Merck Completes Acquisition of SpringWorks Therapeutics to Accelerate Sustainable Growth of its Healthcare Business","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1gFBVV95cUxPZjhmOTMtbVF4RENDV2hkZEtqOEJnMWU0TTh6NVpoTXMycldWR3JsNHA4bl9zMmlVVzFRZmlPTTlpdEtnOFNkYjBWT0huQ2JRTnk1TjJleVhXZzVWYUM0V3U3aEpuRHFsc0w2OFFUeG8xVG8ybGNVVG9NaUFrUnRuSVh6bXBCQ1hkVHQ1ZjhVZEEwSmttdXNVaVk0eDhLVk94ZXJOQmd3VTF3NDJKdW5BUG5QWXBQZXlGUzlNaTZiMEdWcDdFdzhWdVF1TkswM1pZQXhhT213?oc=5","date":"2025-04-28","type":"deal","source":"Reuters","summary":"Germany's Merck KGaA in $3.9 billion deal to buy US biotech firm SpringWorks - Reuters","headline":"Germany's Merck KGaA in $3.9 billion deal to buy US biotech firm SpringWorks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiigFBVV95cUxNYnFIT05Sc0J2ZUh0dF8yTDdJLVhZM1pKdVNONGJ5Zm1hTjFIRmRDbkxGMEJaR3FWblV5SzhXSXdnc0dmUjF4SGN1cE0xXzlXaEdldWQwbUN2U25fYmhLdjRubUxGQl9WQkZKZ3NFV0VxUDR1dmFaVHRWYk1xcUt3RlotblN0eThrcUE?oc=5","date":"2025-04-28","type":"deal","source":"The Pharma Letter","summary":"Merck to acquire rare diseases company SpringWorks - The Pharma Letter","headline":"Merck to acquire rare diseases company SpringWorks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAJBVV95cUxOazc1em1WSlJTY1hZcVp6Y2gyWVhNTC05blRybGU3dEdYWnRMSVFpRXd1UlZHcHplOTA3NFBUWF8xVHZJTkJVM25ueG41bXhpVU9ZNnVpeHVXckJZeDdPSFFRSERCSjJwejQ3UnBtWlY1aVRWV0VNZkk1UkpmM0FWVnVYR0x2UEpQOGdVQjQ5a0FJRU5TMnNiUGhpUWFIWGJocElWVVlqdFlSSU1qSGxHZ1JDeERocllhQUZ2VXlVa2dWVHF0eG9ScEh2M2kxcnRfX1NYVFVnQjR6cENaX0ZmWlFIcG14QU5mclFsblctT3ZJdkFCU2J0SUMxWmtxbFZWelBXTFV2R1NsT0RzQWxhQVNBZG82NnZSRzF5SF9Oci1ZNTJp?oc=5","date":"2025-04-27","type":"deal","source":"Business Wire","summary":"Merck KGaA, Darmstadt, Germany, to Acquire US Biopharma Company SpringWorks Therapeutics to Accelerate Sustainable Growth of Healthcare Business - Business Wire","headline":"Merck KGaA, Darmstadt, Germany, to Acquire US Biopharma Company SpringWorks Therapeutics to Accelerate Sustainable Growt","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxQUFZTbkc2NWdQQUFaRVZPcnp0NXloVUtsRk5kTTlFVThnMGY3UW5aMExsOTc5Uk43V0lhNXBwR3FHZ01OcEptd2tmQ3B5dVltWjhqWW5kNUVrSDNFYUpIaVU3S3pnbTVsMTZYUGRDY1dFeWtDLU8zYUoxczBlcnBKb3BkRUhYX0psOVZJUmFYdk9GTVk3ek1nRDFjSVJETUZ6OF9OU3B0Z2ZFSjIzRFM5Z2tneHBDb3FUbUtsR2hJMWs5TEluYVZJQlZUSG5KZlhEN0tBVlQ3aw?oc=5","date":"2025-04-25","type":"deal","source":"Reuters","summary":"Germany's Merck says in late-stage discussions to buy SpringWorks for $3.5 billion - Reuters","headline":"Germany's Merck says in late-stage discussions to buy SpringWorks for $3.5 billion","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxOcjhJWEpjVGJPY19GX0Jvb3lKQUpQb1J2emlNNWFTYnc1X21SaFRMYnVoRkZWQzZLNE9MYnN6Rk51cW9PSWk3eUo1MWFrdEp5TnJaQW9BenQwRW9pZ0pwWjBUdlExOFlrZk1oa0ppOWRUU1EtRUR5NUZWZFlFVnQ1YjZiMGxXOWREQTZKVmZ2WEZLMW5MNzM4ZENWU3JBQlNzdXNoSDFLVmVzSUI2TXRCRTFJNzZyQndReFBITmV3?oc=5","date":"2025-02-11","type":"regulatory","source":"Reuters","summary":"US FDA approves SpringWorks' genetic disorder drug - Reuters","headline":"US FDA approves SpringWorks' genetic disorder drug","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxOaEJGS1JTOGd6b2tkbW5NelZ6a09FVUdfcEZMNkNUc1F5RkpHY1FLdDFiQlRZaFVvQ1dkX0dndGZ5dXVVcnlBbG8zWVBHY19OamlVWk9JLVBJVEUweHNzTHJCVkgzUDM5SjRrNGpVUmN6NmVlR1d6YzJvUDNrcnh4Tjc0ZUdNYmswT3pTRVlBbVltUE1QTUVuYzQ2OWV6SktNR3FmaTgxUERKNUpBdHdYUG1BY2VKdG5oS0I5bnAtMElobjd5Unc?oc=5","date":"2023-11-28","type":"regulatory","source":"Seeking Alpha","summary":"SpringWorks: Surging On Ogsiveo Approval, Outlook Remains Unclear (NASDAQ:SWTX) - Seeking Alpha","headline":"SpringWorks: Surging On Ogsiveo Approval, Outlook Remains Unclear (NASDAQ:SWTX)","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxNUzZVcTQtZ3NCUmM3dHNpeUtmanNwNWU3TmF1OUtEY3lLNC1heHk5dVE1OXNDb2RveGlsV0tZUWQ0NmxSUTJ3OVpFbVQxV3lXblBmblA0Uk1uSFZqSzRXZ0hYckdSY29zbTA1SWZUSDVoclh3LV9SSmVtdGxEVXB0VmZFSnRlekNxY01LN1k5cHlrbHJDQ2U5djNNb0dPR0V5bzFfam83TTZCY2M?oc=5","date":"2023-04-14","type":"pipeline","source":"Seeking Alpha","summary":"SpringWorks Therapeutics: Pfizer Offshoot With Interesting Pipeline (NASDAQ:SWTX) - Seeking Alpha","headline":"SpringWorks Therapeutics: Pfizer Offshoot With Interesting Pipeline (NASDAQ:SWTX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQQlhtZ1NXTTJtS0JmLXNPemFPbVd5VG5LTFpoaDdtUlQ0TVhZNV9BSnZnSkJLX0FVazIzTnAxbjJnX3BwMTF4czNiTGotMkxXNmdOZU5pRDJ5QTZQRjR6WkdwRDhpYWk5NTFMYVBMQ0dVTEZDeVU5ZE4xdk5SWWwwS3NPOGRTY3Y4ZHhidUp1OTZ1elc0ak52SVhyZ0g5WnMwendQVEczNVRVZmtabzBUTw?oc=5","date":"2022-07-15","type":"pipeline","source":"citybiz","summary":"SpringWorks Therapeutics Appoints Carlos Albán to its Board of Directors - citybiz","headline":"SpringWorks Therapeutics Appoints Carlos Albán to its Board of Directors","sentiment":"neutral"}],"patents":[{"drugName":"nirogacestat","drugSlug":"nirogacestat","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":0},{"drugName":"mirdametinib","drugSlug":"mirdametinib","patentNumber":"","type":"Patent Cliff","expiryDate":"2032-06-01","territory":"US","annualRevenue":0}],"drugCount":2,"phaseCounts":{"phase_3":1,"marketed":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Regeneron Pharmaceuticals","Pfizer","Bristol Myers Squibb"],"therapeuticFocus":["Rare Diseases","Oncology"],"financials":{"source":"sec_edgar+yahoo","revenue":191589000,"revenuePeriod":"2024-12-31","revenueHistory":[{"value":191589000,"period":"2024-12-31"},{"value":5447000,"period":"2023-12-31"},{"value":0,"period":"2022-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":200518000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-258131000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":69751000,"cashHistory":[],"totalAssets":587276000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}